AMG 837: a potent, orally bioavailable GPR40 agonist.

[1]  L. Tang,et al.  AMG 837: A Novel GPR40/FFA1 Agonist that Enhances Insulin Secretion and Lowers Glucose Levels in Rodents , 2011, PloS one.

[2]  A. Howard,et al.  3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR40 agonists. , 2011, Bioorganic & medicinal chemistry letters.

[3]  Toshimasa Tanaka,et al.  Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists. , 2011, Journal of medicinal chemistry.

[4]  M. Faul,et al.  Synthesis of a GPR40 Receptor Agonist , 2010 .

[5]  K. Kristiansen,et al.  Structure-Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469. , 2010, ACS medicinal chemistry letters.

[6]  M. Faul,et al.  Asymmetric syntheses of a GPR40 receptor agonist via diastereoselective and enantioselective conjugate alkynylation , 2010 .

[7]  Masahiro Ito,et al.  Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist. , 2010, ACS medicinal chemistry letters.

[8]  W. Soeller,et al.  Synthesis and SAR of 1,2,3,4-tetrahydroisoquinolin-1-ones as novel G-protein-coupled receptor 40 (GPR40) antagonists. , 2009, Bioorganic & medicinal chemistry letters.

[9]  R. DeFronzo.  From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus , 2009, Diabetes.

[10]  S. Bharate,et al.  Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes , 2009, Expert opinion on therapeutic patents.

[11]  E. Kostenis,et al.  Discovery of potent and selective agonists for the free fatty acid receptor 1 (FFA(1)/GPR40), a potential target for the treatment of type II diabetes. , 2008, Journal of medicinal chemistry.

[12]  Songfeng Lu,et al.  Synthesis and biological evaluation of 3-aryl-3-(4-phenoxy)-propionic acid as a novel series of G protein-coupled receptor 40 agonists. , 2007, Journal of medicinal chemistry.

[13]  A. Goetz,et al.  Solid phase synthesis and SAR of small molecule agonists for the GPR40 receptor. , 2007, Bioorganic & medicinal chemistry letters.

[14]  A. Goetz,et al.  Synthesis and activity of small molecule GPR40 agonists. , 2006, Bioorganic & medicinal chemistry letters.

[15]  G. Scapin,et al.  (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. , 2005, Journal of medicinal chemistry.

[16]  Steven Jupe,et al.  A family of fatty acid binding receptors. , 2005, DNA and cell biology.

[17]  S. Wild,et al.  Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. , 2004, Diabetes care.

[18]  J. Chambers,et al.  The Orphan G Protein-coupled Receptor GPR40 Is Activated by Medium and Long Chain Fatty Acids* , 2003, The Journal of Biological Chemistry.

[19]  Masataka Harada,et al.  Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40 , 2003, Nature.

[20]  B. Olde,et al.  A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs. , 2003, Biochemical and biophysical research communications.

[21]  R. Curi,et al.  Pleiotropic effects of fatty acids on pancreatic β‐cells , 2003 .

[22]  F. Ashcroft,et al.  Sulfonylurea stimulation of insulin secretion. , 2002, Diabetes.

[23]  S. Carloni,et al.  Clean synthesis in water. Part 2: Uncatalysed condensation reaction of Meldrum's acid and aldehydes , 2001 .

[24]  J. McGarry,et al.  Circulating fatty acids are essential for efficient glucose-stimulated insulin secretion after prolonged fasting in humans. , 1998, Diabetes.

[25]  C. Southan,et al.  Inactivation of dopamine beta-hydroxylase by beta-ethynyltyramine: kinetic characterization and covalent modification of an active site peptide. , 1989, Biochemistry.

[26]  W. Oppolzer.  Camphor derivatives as chiral auxiliaries in asymmetric synthesis , 1987 .

[27]  J. Medina,et al.  GPR40 (FFAR1) Modulators , 2008 .

[28]  J. McGarry,et al.  Fatty acids, lipotoxicity and insulin secretion , 1999, Diabetologia.